Zhi-Yong Yang | Head of Discovery Research
ModeX Therapeutics Inc

Zhi-Yong Yang, Head of Discovery Research, ModeX Therapeutics Inc

Zhi-yong Yang, an author of more than 110 scientific publications with over 35 years of research experiences in academy, big pharma and biotech startup, leading the effort in developing novel vaccines and biotherapeutics against infectious diseases and cancers using multi-specific antibody technologies. In 2020, he joined ModeX Therapeutics as the head of research, continuing his pursue in developing multi-specific Ab technology and nucleic acid delivery technology, and immunotherapeutic to treat cancers and infectious diseases.

Appearances:



Festival of Biologics Day 1 @ 14:00

Multispecific Targeting for the Treatment of Infections and Cancer

  • Multi-targeting is a way of addressing tumor heterogeneity and combining biological pathways.
  • Multispecific Ab platform provides the feasibility of integrating 3 to 4 independent binders in one molecule.
  • Our effort in combination of anti-CD3/CD28 demonstrated improved T cell activation/survival, and significantly enhanced therapeutic effect of the trispecific Abs both in vitro and in vivo.
last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers